RenovoRx, Inc. (RNXT)

US — Healthcare Sector
Peers: AXLA  ADIL  BTTX  KTTA  ZIVO  QNRX  ABIO  NTRB  LGVN  VRAX  ANEB  SABS  MNPR  ELDN  TPST  IKNA  CBIO 

Automate Your Wheel Strategy on RNXT

With Tiblio's Option Bot, you can configure your own wheel strategy including RNXT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol RNXT
  • Rev/Share 0.0076
  • Book/Share 0.4191
  • PB 3.2214
  • Debt/Equity 0.0141
  • CurrentRatio 9.0697
  • ROIC -1.0108

 

  • MktCap 49372470.0
  • FreeCF/Share -0.3286
  • PFCF -4.786
  • PE -4.1725
  • Debt/Assets 0.0116
  • DivYield 0
  • ROE -1.1958

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 2
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript
RNXT
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral

RenovoRx, Inc. (NASDAQ:RNXT ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Valter Pinto - IR Ramtin Agah - Founder and Chief Medical Officer Shaun Bagai - CEO Ronald Kocak - VP Controller and Principal Accounting Officer Conference Call Participants Rafay Khalid - Ascendiant Capital Markets Operator Good afternoon, everyone, and welcome to the RenovoRx Q1 2025 Financial and Operational Highlights Conference Call. All participants will be in a listen-only mode.

Read More
image for news RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript
RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates
RNXT
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Neutral

RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago.

Read More
image for news RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates
RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET
RNXT
Published: May 01, 2025 by: Business Wire
Sentiment: Neutral

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced it will host its first quarter 2025 financial results conference call on May 15th, 2025, at 4:30 p.m. ET. Additional details will be available in the Investor Relations section of the Company's website at https://ir.renovorx.com/. Ev.

Read More
image for news RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET
Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial
RNXT
Published: April 29, 2025 by: Business Wire
Sentiment: Neutral

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Johns Hopkins Medicine is now initiated to enroll patients with locally advanced pancreatic cancer (LAPC) in RenovoRx's ongoing Phase III TIGeR-PaC clinical trial. Johns Hopkins Medicine becomes the newest addition to a disting.

Read More
image for news Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th
RNXT
Published: April 04, 2025 by: Business Wire
Sentiment: Neutral

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will present at the LD Micro Invitational XV: New York 2025 conference taking place at the Westin Grand Central Hotel, New York, NY on April 10, 2025. Mr. Bagai will discuss recent corporate m.

Read More
image for news RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

About RenovoRx, Inc. (RNXT)

  • IPO Date 2021-08-26
  • Website https://renovorx.com
  • Industry Biotechnology
  • CEO Mr. Shaun R. Bagai
  • Employees 10

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.